Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3161901 | 1.00 | HTT (0.49) | HTTPOLBSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3161069 | 0.75 | — | — | |
| SCHEMBL20625465 | 0.73 | XDH (0.30) | — | |
| SCHEMBL24129339 | 0.73 | HTT (0.30) | HTT | |
| SCHEMBL24931289 | 0.73 | HTT (0.30) | HTT | |
| SCHEMBL17768780 | 0.70 | RET (0.43) | HTTKDM4E | |
| SCHEMBL17768781 | 0.70 | RET (0.43) | HTTKDM4E | |
| SCHEMBL2936179 | 0.65 | — | — | |
| SCHEMBL2649388 | 0.64 | — | — | |
| SCHEMBL16321601 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | US | disclosed |
| EP-3220910-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | Merck Sharp & Dohme Corp. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081290-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| EP-1546107-B1 | COX-2 INHIBITING PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7446117-B2 | Cox-2 inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20060040988-A1 | Cox-2 Inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1546107-A1 | COX-2 INHIBITING PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004024691-A1 | COX-2 INHIBITING PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040988-A1 | Cox-2 Inhibiting pyridine derivatives | PTGS2, PTGES2, PTGS1 | HTT 4440/4885POLB 2468/4885SMN1; SMN2 2360/4885 |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | HTT 109/4885POLB 4512/4885SMN1; SMN2 738/4885 |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | HTT 109/4885POLB 4512/4885SMN1; SMN2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.